IUSCC-0678

Through this protocol, UNMCCC and its partners will establish and maintain a unique repository of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected from thousands of patients 18 years of age or older who have cancer or are at risk of developing cancer. In this protocol, the investigators require the permission of patients to study their answers to survey questions that may be collected as part of their regular clinical care, permission to study their medical and related records, and permission to collect excess tissues removed at the time of planned surgery, an additional tumor sampling (needle passes) at the time of planned diagnostic biopsies, previously collected, stored tumor tissue (if available), blood, and/or other biological samples. Additional research tumor samples may be collected at the time of any diagnostic needle biopsy or endoscopic biopsy or, if available, patient tissue from a previous procedure will be obtained and utilized as needed. Clinical and related data will be collected on all patients from the time of initial entry into the study and will continue for life.

Inclusion Criteria:

* 18 years of age and older.
* Has a diagnosis of cancer or is suspected of having cancer.
* Able to understand and sign the Informed Consent form directly.
* Pregnant women are permitted to be enrolled.

Exclusion Criteria:

* Prisoners

Bones and Joints
Breast
Multiple Myeloma

IU Health Arnett

• IU Health Arnett Cancer Care Clinic
• IU Health Arnett Hospital

• IU Health Ball Memorial Hospital

• Eskenazi Hospital
• IU Health Methodist Hospital
• IU Health North/ Schwarz Cancer Center
• Indiana University Genetics Biobank (IUGB)
• Indiana University Hospital / IU Simon Cancer Center
• Riley Hospital for Children
• Spring Mill Medical Center

• The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors
  Eljilany I;Saghand PG;Chen J;Ratan A;McCarter M;Carpten J;Colman H;Ikeguchi AP;Puzanov I;Arnold S;Churchman M;Hwu P;Conejo-Garcia J;Dalton WS;Weiner GJ;El Naqa IM;Tarhini AA;
• Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy
  Eljilany I;Coleman S;Tan AC;McCarter MD;Carpten J;Colman H;Naqash AR;Puzanov I;Arnold SM;Churchman ML;Spakowicz D;Salhia B;Marin J;Ganesan S;Ratan A;Shriver C;Hwu P;Dalton WS;Weiner GJ;Conejo-Garcia JR;Rodriguez P;Tarhini AA;